CC
MRNA icon

Centiva Capital’s Moderna MRNA Stock Holding History

Centiva Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.85M Buy
+134,800
New +$6.29M 0.05% 239
2025
Q3 		– Sell
-150,000
Closed -$4.14M – 1574
2025
Q2 		$4.14M Buy
+150,000
New +$3.95M 0.07% 173
2024
Q4 		– Sell
-5,100
Closed -$341K – 2142
2024
Q3 		$341K Buy
5,100
+1,500
+42% +$138K 0.01% 1501
2024
Q2 		$428K Buy
+3,600
New +$456K 0.01% 1253
2024
Q1 		– Sell
-5,000
Closed -$497K – 2062
2023
Q4 		$497K Buy
+5,000
New +$421K 0.01% 964
2023
Q3 		– Sell
-22,500
Closed -$2.73M – 1952
2023
Q2 		$2.73M Sell
22,500
-12,900
-36% -$1.72M 0.06% 302
2023
Q1 		$5.44M Buy
35,400
+300
+0.9% +$49.5K 0.13% 161
2022
Q4 		$6.3M Sell
35,100
-21,500
-38% -$3.52M 0.18% 111
2022
Q3 		$6.7M Sell
56,600
-22,000
-28% -$3.34M 0.13% 113
2022
Q2 		$11.2M Buy
78,600
+29,000
+58% +$4.15M 0.27% 43
2022
Q1 		$8.54M Sell
49,600
-25,000
-34% -$4.21M 0.16% 81
2021
Q4 		$18.9M Buy
74,600
+68,830
+1,193% +$20.1M 0.39% 43
2021
Q3 		$2.22M Sell
5,770
-70,030
-92% -$25.8M 0.14% 154
2021
Q2 		$17.8M Buy
75,800
+13,500
+22% +$2.41M 0.42% 35
2021
Q1 		$8.16M Buy
+62,300
New +$9.03M 0.31% 55

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Centiva Capital's MRNA Position: Q1 2026 in Review

Centiva Capital opened a new position in Moderna (MRNA) in Q1 2026: 2,733 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #1342 among its holdings. This is a return to the name: Centiva Capital previously reported a position in MRNA as recently as Q2 2025.

Centiva Capital first reported a position in MRNA in Q2 2020 and has held it in 15 quarters since. The position peaked at $5.92M in Q1 2022. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Centiva Capital held 2,733 shares of Moderna worth $139K as of Q1 2026.
  • Moderna was a new Centiva Capital position in Q1 2026.
  • Moderna made up ﹤0.01% of Centiva Capital's portfolio in Q1 2026, its #1342 holding.
  • Centiva Capital first reported a position in Moderna in Q2 2020 and has held it in 15 quarters since.
  • Centiva Capital's Moderna position peaked at $5.92M in Q1 2022.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.